Should peri-gastrectomy gastric acidity be our focus among gastric cancer patients?

Table 1 General clinicopathological features of patients enrolled in the study (mean ± SD)

	Total gastrectomy	Distal gastrectomy	Proximal gastrectomy
Number of patients	35	34	30
Gender (male/female)	20/15	19/15	19/11
Smoking (yes/no)	19/16	18/16	18/12
Drinking (yes/no)	17/18	18/16	17/13
Age (yr)	62.49 ± 9.69	63.68 ± 9.48	59.40 ± 10.61
Body mass index (kg/m2)	20.55 ± 4.02	20.92 ± 2.57	19.70 ± 2.43
Hemoglobin (g/L)	114.83 ± 26.00	125.59 ± 24.99	122.23 ± 21.46
Lymphocyte count (109/L)	1.61 ± 0.50	1.34 ± 0.47	1.65 ± 0.51
Albumin (g/L)	38.43 ± 4.92	41.58 ± 3.50	40.99 ± 1.85
Pre-albumin (mg/L)	252.20 ± 60.65	282.71 ± 70.35	262.23 ± 45.65
RDQ score pre-operation	3.77 ± 2.58	3.35 ± 2.36	3.50 ± 2.36
GERD-Q score pre-operation	1.49 ± 1.15	1.47 ± 1.05	1.63 ± 1.40
Days in hospital pre-operation	3.09 ± 0.92	3.06 ± 0.92	3.00 ± 0.87
Days to peri-bed activities post-operation	1.14 ± 0.36	1.12 ± 0.33	1.13 ± 0.35
Days to borborygmus recovery post-operation	1.51 ± 0.51	1.56 ± 0.50	1.57 ± 0.50
Flatus duration post-operation (d)	3.11 ± 0.63	3.29 ± 0.80	3.47 ± 0.68
Transverse diameter of tumor (cm)	4.71 ± 1.87	4.90 ± 1.46	4.78 ± 2.04
Longitudinal diameter of tumor (cm)	4.06 ± 1.86	4.20 ± 1.15	4.40 ± 1.54
Depth of tumor (cm)	1.41 ± 0.64	1.66 ± 0.47	1.16 ± 0.66
Tumor stage (early/advanced)	4/31	5/29	3/27
Tumor differentiation (well/moderately/poorly)	6/15/14	7/12/15	4/13/13
Tumor TNM classification (I/II/III)1	4/5/26	7/6/21	3/8/19
Postoperative NRS score	3.34 ± 0.97	3.32 ± 0.98	3.30 ± 1.02

¹There was no patient with tumor-node-metastasis (TNM) IV tumor in our study. RDQ: Reflux disease questionnaire; GERD-Q: Gastroesophageal reflux disease questionnaire; NRS: Numerical rating scale.